<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34080180</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2249</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>206</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical and experimental immunology</Title>
          <ISOAbbreviation>Clin Exp Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Magnetic resonance imaging in neuromyelitis optica spectrum disorder.</ArticleTitle>
        <Pagination>
          <StartPage>251</StartPage>
          <EndPage>265</EndPage>
          <MedlinePgn>251-265</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/cei.13630</ELocationID>
        <Abstract>
          <AbstractText>Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disease of the central nervous system (CNS) associated with antibodies to aquaporin-4 (AQP4), which has distinct clinical, radiological and pathological features, but also has some overlap with multiple sclerosis and myelin oligodendrocyte glycoprotein (MOG) antibody associated disease. Early recognition of NMOSD is important because of differing responses to both acute and preventive therapy. Magnetic resonance (MR) imaging has proved essential in this process. Key MR imaging clues to the diagnosis of NMOSD are longitudinally extensive lesions of the optic nerve (more than half the length) and spinal cord (three or more vertebral segments), bilateral optic nerve lesions and lesions of the optic chiasm, area postrema, floor of the IV ventricle, periaqueductal grey matter, hypothalamus and walls of the III ventricle. Other NMOSD-specific lesions are denoted by their unique morphology: heterogeneous lesions of the corpus callosum, 'cloud-like' gadolinium (Gd)-enhancing white matter lesions and 'bright spotty' lesions of the spinal cord. Other lesions described in NMOSD, including linear periventricular peri-ependymal lesions and patch subcortical white matter lesions, may be less specific. The use of advanced MR imaging techniques is yielding further useful information regarding focal degeneration of the thalamus and optic radiation in NMOSD and suggests that paramagnetic rim patterns and changes in normal appearing white matter are specific to MS. MR imaging is crucial in the early recognition of NMOSD and in directing testing for AQP4 antibodies and guiding immediate acute treatment decisions. Increasingly, MR imaging is playing a role in diagnosing seronegative cases of NMOSD.</AbstractText>
          <CopyrightInformation>© 2021 British Society for Immunology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Clarke</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Menzies Health Institute Queensland, Gold Coast Campus, Griffith University, Nathan, QLD, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Princess Alexandra Hospital, Brisbane, QLD, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arnett</LastName>
            <ForeName>Simon</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Menzies Health Institute Queensland, Gold Coast Campus, Griffith University, Nathan, QLD, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Gold Coast University Hospital, Southport, QLD, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lilley</LastName>
            <ForeName>Kate</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Menzies Health Institute Queensland, Gold Coast Campus, Griffith University, Nathan, QLD, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Gold Coast University Hospital, Southport, QLD, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liao</LastName>
            <ForeName>Jacky</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Menzies Health Institute Queensland, Gold Coast Campus, Griffith University, Nathan, QLD, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bhuta</LastName>
            <ForeName>Sandeep</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Menzies Health Institute Queensland, Gold Coast Campus, Griffith University, Nathan, QLD, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Gold Coast University Hospital, Southport, QLD, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Broadley</LastName>
            <ForeName>Simon A</ForeName>
            <Initials>SA</Initials>
            <Identifier Source="ORCID">0000-0002-9429-4307</Identifier>
            <AffiliationInfo>
              <Affiliation>Menzies Health Institute Queensland, Gold Coast Campus, Griffith University, Nathan, QLD, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Gold Coast University Hospital, Southport, QLD, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Clin Exp Immunol</MedlineTA>
        <NlmUniqueID>0057202</NlmUniqueID>
        <ISSNLinking>0009-9104</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C496030">AQP4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051401">Aquaporin 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D051401" MajorTopicYN="N">Aquaporin 4</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009471" MajorTopicYN="N">Neuromyelitis Optica</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009900" MajorTopicYN="N">Optic Nerve</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">diagnosis</Keyword>
        <Keyword MajorTopicYN="Y">magnetic resonance imaging</Keyword>
        <Keyword MajorTopicYN="Y">multiple sclerosis</Keyword>
        <Keyword MajorTopicYN="Y">neuromyelitis optica</Keyword>
      </KeywordList>
      <CoiStatement>Simon A. Broadley has received honoraria for attendance at advisory boards and travel sponsorship from Bayer‐Schering, Biogen‐Idec, Merck‐Serono, Novartis and Sanofi‐Genzyme, has received speaker’s honoraria from Biogen‐Idec and Genzyme, is an investigator in clinical trials sponsored by Biogen Idec, Novartis and Genzyme and was the recipient of an unencumbered research grant from Biogen‐Idec. Laura Clarke, Simon Arnett, Kate Lilley, Jacky Liao and Sandeep Bhuta report no disclosures.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>12</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>53</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34080180</ArticleId>
        <ArticleId IdType="pmc">PMC8561702</ArticleId>
        <ArticleId IdType="doi">10.1111/cei.13630</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Devic E. Myélite subaiguë compliquée de névrite optique. Bull Med. 1894;8:1033–4.</Citation>
        </Reference>
        <Reference>
          <Citation>
Devic E. Acute lumbar spinal myelitis with optic neuritis, autopsy. French Cong Med. 1895;1:434–9.</Citation>
        </Reference>
        <Reference>
          <Citation>
Albutt FC. On the ophthalmoscopic signs of spinal cord disease. Lancet
1870;i:76–8.</Citation>
        </Reference>
        <Reference>
          <Citation>
Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet
2004;364:2106–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15589308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Paul F, Jarius S, Aktas O, Bluthner M, Bauer O, Appelhans H, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLOS Med. 2007;4:e133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1852124</ArticleId>
            <ArticleId IdType="pubmed">17439296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jarius S, Wildemann B. Devic’s index case: a critical reappraisal – AQP4‐IgG‐mediated neuromyelitis optica spectrum disorder, or rather MOG encephalomyelitis?
J Neurol Sci. 2019;407:116396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31726278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17706564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ramanathan S, Dale RC, Brilot F. Anti‐MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. 2016;15:307–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26708342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, et al. Central nervous system sarcoidosis – diagnosis and management. Q J Med. 1999;92:103–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10209662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kidd D, Burton B, Plant GT, Graham EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain
2003;126:276–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12538397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 2020;11:501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7332882</ArticleId>
            <ArticleId IdType="pubmed">32670177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International panel for NMOD. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology
2015;85:177–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4515040</ArticleId>
            <ArticleId IdType="pubmed">26092914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Khalilidehkordi E, Clarke L, Arnett S, Bukhari W, Jimenez Sanchez S, O'Gorman C, et al. Relapse patterns in NMOSD: evidence for earlier occurrence of optic neuritis and possible seasonal variation. Front Neurol. 2020;11:537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7308484</ArticleId>
            <ArticleId IdType="pubmed">32612571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bukhari W, Clarke L, O’Gorman C, Khalilidehkordi E, Arnett S, Prain KM, et al. The clinical profile of NMOSD in Australia and New Zealand. J Neurol. 2020;267:1431–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32006158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, et al. Neuromyelitis optica study G. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016;79:206–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26537743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim HJ, Paul F, Lana‐Peixoto MA, Tenembaum S, Asgari N, Palace J, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology
2015;84:1165–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4371410</ArticleId>
            <ArticleId IdType="pubmed">25695963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bennett JL, de Seze
J
, Lana‐Peixoto M, Palace J, Waldman A, Schippling S, et al. Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Sclerosis. 2015;21:678–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4425816</ArticleId>
            <ArticleId IdType="pubmed">25662342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic‐spinal multiple sclerosis binds to the aquaporin‐4 water channel. J Exp Med. 2005;202:473–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2212860</ArticleId>
            <ArticleId IdType="pubmed">16087714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lu M, Lee MD, Smith BL, Jung JS, Agre P, Verdijk MA, et al. The human AQP4 gene: definition of the locus encoding two water channel polypeptides in brain. Proc Natl Acad Sci USA. 1996;93:10908–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC38256</ArticleId>
            <ArticleId IdType="pubmed">8855281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rossi A, Crane JM, Verkman AS. Aquaporin‐4 Mz isoform: brain expression, supramolecular assembly and neuromyelitis optica antibody binding. Glia
2011;59:1056–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3327643</ArticleId>
            <ArticleId IdType="pubmed">21491501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Verkman AS, Ratelade J, Rossi A, Zhang H, Tradtrantip L. Aquaporin‐4: orthogonal array assembly, CNS functions, and role in neuromyelitis optica. Acta Pharmacol Sin. 2011;32:702–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3601948</ArticleId>
            <ArticleId IdType="pubmed">21552296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nicchia GP, Mastrototaro M, Rossi A, Pisani F, Tortorella C, Ruggieri M, et al. Aquaporin‐4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia
2009;57:1363–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19229993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Crane JM, Lam C, Rossi A, Gupta T, Bennett JL, Verkman AS. Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin‐4 M1/M23 isoforms and orthogonal arrays. J Biol Chem. 2011;286:16516–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3091256</ArticleId>
            <ArticleId IdType="pubmed">21454592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Waters PJ, Pittock SJ, Bennett JL, Jarius S, Weinshenker BG, Wingerchuk DM. Evaluation of aquaporin‐4 antibody assays. Clin Exp Neuroimmunol. 2014;5:290–303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5102503</ArticleId>
            <ArticleId IdType="pubmed">27840658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Prain K, Woodhall M, Vincent A, Ramanathan S, Barnett MH, Bundell C, et al.; the Australian and New Zealand NMO Collaboration
. AQP4 antibody assay sensitivity comparison in the era of the diagnostic criteria for NMOSD. Front Neurol. 2015;2019:1028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6787171</ArticleId>
            <ArticleId IdType="pubmed">31636597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Watanabe M, Nakamura Y, Michalak Z, Isobe N, Barro C, Leppert D, et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology
2019;93:e1299–e1311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31471502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, et al. Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry. 2017;88:632–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28550069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Flanagan EP, Cabre P, Weinshenker BG, St Sauver J, Jacobson DJ, Majed M, et al. Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016;79:775–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4988933</ArticleId>
            <ArticleId IdType="pubmed">26891082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jacob A, Panicker J, Lythgoe D, Elsone L, Mutch K, Wilson M, et al. The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J Neurol. 2013;260:2134–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23689970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, et al. Consortium GIC, Biorepository for neuromyelitis O
. Demographic and clinical features of neuromyelitis optica: a review. Mult Sclerosis. 2015;21:845–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4463026</ArticleId>
            <ArticleId IdType="pubmed">25921037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wingerchuk DM. Evidence for humoral autoimmunity in neuromyelitis optica. Neurol Res. 2006;28:348–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16687064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asherson RA, Khamashta MA, Gil A, Vazquez JJ, Chan O, Baguley E, et al. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus‐like disease, and the primary antiphospholipid syndrome. Am J Med. 1989;86:391–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2494884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Goel D, Reddy SR, Sundaram C, Prayaga AK, Rajasekhar L, Narsimulu G. Active necrotizing cerebral vasculitis in systemic lupus erythematosus. Neuropathology
2007;27:561–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18021377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Alexander GE, Provost TT, Stevens MB, Alexander EL. Sjogren syndrome: central nervous system manifestations. Neurology
1981;31:1391–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6273765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Raymond NT, Langley JD, Goyder E, Botha JL, Burden AC, Hearnshaw JR. Insulin treated diabetes mellitus: causes of death determined from record linkage of population based registers in Leicestershire, UK. J Epidemiol Commun Health. 1995;49:570–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1060170</ArticleId>
            <ArticleId IdType="pubmed">8596090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Squizzato A, Gerdes VE, Brandjes DP, Buller HR, Stam J. Thyroid diseases and cerebrovascular disease. Stroke
2005;36:2302–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16179578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra‐cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain
2010;133:349–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2822632</ArticleId>
            <ArticleId IdType="pubmed">20047900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Parratt JD, Prineas JW. Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes. Mult Sclerosis. 2010;16:1156–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20823059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain
2007;130:1224–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17405762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bukhari W, Barnett MH, Prain K, Broadley SA. Molecular pathogenesis of neuromyelitis optica. Int J Mol Sci. 2012;13:12970–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3497307</ArticleId>
            <ArticleId IdType="pubmed">23202933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nielsen S, Nagelhus EA, Amiry‐Moghaddam M, Bourque C, Agre P, Ottersen OP. Specialized membrane domains for water transport in glial cells: high‐resolution immunogold cytochemistry of aquaporin‐4 in rat brain. J Neurosci. 1997;17:171–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6793699</ArticleId>
            <ArticleId IdType="pubmed">8987746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006;63:964–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16831965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bradl M, Reindl M, Lassmann H. Mechanisms for lesion localization in neuromyelitis optica spectrum disorders. Curr Opin Neurol. 2018;31:325–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5959204</ArticleId>
            <ArticleId IdType="pubmed">29465432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pittock SJ, Lennon VA. Aquaporin‐4 autoantibodies in a paraneoplastic context. Arch Neurol. 2008;65:629–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18474738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim SH, Kim W, Huh SY, Lee KY, Jung IJ, Kim HJ. Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti‐aquaporin‐4 antibody levels. J Clin Neurol. 2013;9:36–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3543908</ArticleId>
            <ArticleId IdType="pubmed">23346159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K et al. Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm. 2018;5:e504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6192689</ArticleId>
            <ArticleId IdType="pubmed">30345331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Akaishi T, Takeshita T, Himori N, Takahashi T, Misu T, Ogawa R, et al. Rapid administration of high‐dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4‐IgG‐positive NMOSD. Front Neurol. 2020;11:932.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7505044</ArticleId>
            <ArticleId IdType="pubmed">33013632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?
Multiple Sclerosis. 2012;18:1480–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22354738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yoshii F, Moriya Y, Ohnuki T, Ryo M, Takahashi W. Fingolimod‐induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder. Mult Sclerosis Relat Disord. 2016;7:53–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27237757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kitley J, Evangelou N, Kuker W, Jacob A, Leite MI, Palace J. Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab. J Neurol Sci. 2014;339:223–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24576801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17:1019–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20528913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N‐MOmentum): a double‐blind, randomised placebo‐controlled phase 2/3 trial. Lancet. 2019;394:1352–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31495497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double‐blind, multicentre, placebo‐controlled phase 3 trial. Lancet Neurol. 2020;19:402–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7935419</ArticleId>
            <ArticleId IdType="pubmed">32333898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in aquaporin‐4‐positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:614–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31050279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Buch D, Savatovsky J, Gout O, Vignal C, Deschamps R. Combined brain and anterior visual pathways’ MRIs assist in early identification of neuromyelitis optica spectrum disorder at onset of optic neuritis. Acta Neurol Belg. 2017;117:67–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27804015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Carnero Contentti E, Delgado‐García G, López PA, Criniti J, Pettinicchi JP, Correa‐Díaz EP, et al. Acute optic nerve lesions in first‐ever NMOSD‐related optic neuritis using conventional brain MRI: a Latin American multicenter study. Mult Sclerosis Relat Disord. 2020;46:102558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33032052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mealy MA, Whetstone A, Orman G, Izbudak I, Calabresi PA, Levy M. Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis. J Neurol Sci. 2015;355:59–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4492883</ArticleId>
            <ArticleId IdType="pubmed">26026942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pula JH, Kattah JC, Keung B, Wang H, Daily J. Longitudinally extensive optic neuritis in neuromyelitis optica spectrum disorder. J Neurol Sci. 2014;345:209–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25125046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Khanna S, Sharma A, Huecker J, Gordon M, Naismith RT, Van Stavern GP. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuro Ophthalmol. 2012;32:216–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22659839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lim YM, Pyun SY, Lim HT, Jeong IH, Kim KK. First‐ever optic neuritis: distinguishing subsequent neuromyelitis optica from multiple sclerosis. Neurol Sci. 2014;35:781–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24487628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li H, Zhou H, Sun J, Wang H, Wang Y, Wang Z, et al. Optic perineuritis and its association with autoimmune diseases. Front Neurol. 2020;11:627077.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7880123</ArticleId>
            <ArticleId IdType="pubmed">33584521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ramanathan S, Fraser C, Curnow SR, Ghaly M, Leventer RJ, Lechner‐Scott J, et al. Uveitis and optic perineuritis in the context of myelin oligodendrocyte glycoprotein antibody seropositivity. Eur J Neurol. 2019;26:1137–e75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30748058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nakashima I, Fujihara K, Miyazawa I, Misu T, Narikawa K, Nakamura M, et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO‐IgG. J Neurol Neurosurg Psychiatry. 2006;77:1073–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2077753</ArticleId>
            <ArticleId IdType="pubmed">16505005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chan KH, Tsang KL, Fong GC, Ho SL, Cheung RT, Mak W. Idiopathic inflammatory demyelinating disorders after acute transverse myelitis. Eur J Neurol. 2006;13:862–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16879297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cassinotto C, Deramond H, Olindo S, Aveillan M, Smadja D, Cabre P. MRI of the spinal cord in neuromyelitis optica and recurrent longitudinal extensive myelitis. J Neuroradiol. 2009;36:199–205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19223076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lu Z, Qiu W, Zou Y, Lv K, Long Y, You W, et al. Characteristic linear lesions and longitudinally extensive spinal cord lesions in Chinese patients with neuromyelitis optica. J Neurol Sci. 2010;293:92–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20346462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li R, Qiu W, Lu Z, Dai Y, Wu A, Long Y, et al. Acute transverse myelitis in demyelinating diseases among the Chinese. J Neurol. 2011;258:2206–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21590279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang KC, Tsai CP, Lee CL, Chen SY, Chen SJ. The prevalence of long spinal cord lesions and anti‐aquaporin 4 antibodies in neuromyelitis optica patients in Taiwan. Eur Neurol. 2011;65:99–104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21273778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Downer JJ, Leite MI, Carter R, Palace J, Kuker W, Quaghebeur G. Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?
Neuroradiology
2012;54:279–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21553012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lalan S, Khan M, Schlakman B, Penman A, Gatlin J, Herndon R. Differentiation of neuromyelitis optica from multiple sclerosis on spinal magnetic resonance imaging. Int J MS Care. 2012;14:209–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3882989</ArticleId>
            <ArticleId IdType="pubmed">24453753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chan KH, Lee R, Lee JC, Tse AC, Pang SY, Lau GK, et al. Central nervous system inflammatory demyelinating disorders among Hong Kong Chinese. J Neuroimmunol. 2013;262:100–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23838529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kiyat‐Atamer A, Ekizoglu E, Tuzun E, Kurtuncu M, Shugaiv E, Akman‐Demir G, et al. Long‐term MRI findings in neuromyelitis optica: seropositive versus seronegative patients. Eur J Neurol. 2013;20:781–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23279782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Barhate KS, Ganeshan M, Singhal BS. A clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort. Ann Indian Acad Neurol. 2014;17:77–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3992776</ArticleId>
            <ArticleId IdType="pubmed">24753665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lin A, Zhu J, Yao X, Lin S, Murong S, Li Z. Clinical manifestations and spinal cord magnetic resonance imaging findings in Chinese neuromyelitis optica patients. Eur Neurol. 2014;71:35–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24281652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu Y, Zhao G, Yu H, Lyu C, Li Z, Wu Z. Differentiation of neuromyelitis optica from multiple sclerosis in a cohort from the mainland of China. Chin Med J. 2014;127:3213–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25266515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Flanagan EP, Weinshenker BG, Krecke KN, Lennon VA, Lucchinetti CF, McKeon A, et al. Short myelitis lesions in aquaporin‐4‐IgG‐positive neuromyelitis optica spectrum disorders. JAMA Neurol. 2015;72:81–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4552048</ArticleId>
            <ArticleId IdType="pubmed">25384099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cai W, Tan S, Zhang L, Shan Y, Wang Y, Lin Y, et al. Linear lesions may assist early diagnosis of neuromyelitis optica and longitudinally extensive transverse myelitis, two subtypes of NMOSD. J Neurol Sci. 2016;360:88–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26723980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bigaut K, Lambert C, Kremer L, Lebrun C, Cohen M, Ciron J, et al. Atypical myelitis in patients with multiple sclerosis: characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders. Mult Sclerosis. 2021;27:232–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32077365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63:390–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16533966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asgari N, Skejoe HP, Lillevang ST, Steenstrup T, Stenager E, Kyvik KO. Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population‐based, descriptive study. BMC Neurol. 2013;13:33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3622587</ArticleId>
            <ArticleId IdType="pubmed">23566260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Iorio R, Damato V, Mirabella M, Evoli A, Marti A, Plantone D, et al. Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin‐4 autoantibodies. J Neurol. 2013;260:2396–402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23793787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dubey D, Pittock SJ, Krecke KN, Flanagan EP. Association of extension of cervical cord lesion and area postrema syndrome with neuromyelitis optica spectrum disorder. JAMA Neurol. 2017;74:359–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28097302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cobo‐Calvo A, Sepulveda M, Bernard‐Valnet R, Ruiz A, Brassat D, Martinez‐Yelamos S, et al. Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: clinical and prognostic implications. Mult Sclerosis. 2016;22:312–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26209592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hyun JW, Kim SH, Huh SY, Kim W, Yun J, Joung A, et al. Idiopathic aquaporin‐4 antibody negative longitudinally extensive transverse myelitis. Mult Sclerosis. 2015;21:710–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25305252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rempe T, Tarhan B, Rodriguez E, Viswanathan VT, Gyang TV, Carlson A, et al. Anti‐MOG associated disorder‐Clinical and radiological characteristics compared to AQP4‐IgG+ NMOSD‐A single‐center experience. Mult Sclerosis Relat Disord. 2021;48:102718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33388560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shahriari M, Sotirchos ES, Newsome SD, Yousem DM. MOGAD: how it differs from and resembles other neuroinflammatory disorders. Am J Roentgenol. 2021;216:1031–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32755221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Komatsu J, Sakai K, Nakada M, Iwasa K, Yamada M. Long spinal cord lesions in a patient with pathologically proven multiple sclerosis. J Clin Neurosci. 2017;42:106–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28465080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asnafi S, Morris PP, Sechi E, Pittock SJ, Weinshenker BG, Palace J, et al. The frequency of longitudinally extensive transverse myelitis in MS: a population‐based study. Mult Sclerosis Relat Disord. 2020;37:101487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31707235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li Y, Xie P, Lv F, Mu J, Li Q, Yang Q, et al. Brain magnetic resonance imaging abnormalities in neuromyelitis optica. Acta Neurol Scand. 2008;118:218–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18384459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chan KH, Tse CT, Chung CP, Lee RL, Kwan JS, Ho PW, et al. Brain involvement in neuromyelitis optica spectrum disorders. Arch Neurol. 2011;68:1432–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22084126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Huh SY, Min JH, Kim W, Kim SH, Kim HJ, Kim BJ, et al. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Mult Sclerosis. 2014;20:695–704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24072726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim W, Park MS, Lee SH, Kim SH, Jung IJ, Takahashi T, et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin‐4 autoimmunity. Mult Sclerosis. 2010;16:1229–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20685766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yonezu T, Ito S, Mori M, Ogawa Y, Makino T, Uzawa A, et al. ‘Bright spotty lesions’ on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Mult Sclerosis. 2014;20:331–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23828869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kister I, Johnson E, Raz E, Babb J, Loh J, Shepherd TM. Specific MRI findings help distinguish acute transverse myelitis of neuromyelitis optica from spinal cord infarction. Mult Sclerosis Relat Disord. 2016;9:62–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27645347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pekcevik Y, Mitchell CH, Mealy MA, Orman G, Lee IH, Newsome SD, et al. Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging. Mult Sclerosis. 2016;22:302–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4797654</ArticleId>
            <ArticleId IdType="pubmed">26209588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Salama S, Levy M. Bright spotty lesions as an imaging marker for neuromyelitis optica spectrum disorder. Mult Sclerosis J. 2021. doi:10.1177/1352458521994259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458521994259</ArticleId>
            <ArticleId IdType="pubmed">33635151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rabasté S, Cobo‐Calvo A, Nistiriuc‐Muntean V, Vukusic S, Marignier R, Cotton F, et al. Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy. J Neuroradiol. 2021;48:28–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32407908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Adoni T, Lino AM, da Gama
PD
, Apostolos‐Pereira SL, Marchiori PE, Kok F, et al. Recurrent neuromyelitis optica in Brazilian patients: clinical, immunological, and neuroimaging characteristics. Mult Sclerosis. 2010;16:81–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19995833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yokote H, Nose Y, Ishibashi S, Tanaka K, Takahashi T, Fujihara K, et al. Spinal cord ring enhancement in patients with neuromyelitis optica. Acta Neurol Scand. 2015;132:37–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25639599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zalewski NL, Morris PP, Weinshenker BG, Lucchinetti CF, Guo Y, Pittock SJ, et al. Ring‐enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2017;88:218–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27913626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dumrikarnlert C, Siritho S, Chulapimphan P, Ngamsombat C, Satukijchai C, Prayoonwiwat N. The characteristics of spinal imaging in different types of demyelinating diseases. J Neurol Sci. 2017;372:138–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28017200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Carnero Contentti E, Daccach Marques V, Soto de Castillo I, Tkachuk V, Antunes Barreira A, Armas E, et al. Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: a cohort of Latin American patients. Mult Sclerosis Relat Disord. 2018;19:73‐8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29156226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Abdullah S, Fadzli F, Ramli N, Tan CT. There is less MRI brain lesions and no characteristic MRI Brain findings in IIDDs patients with positive AQP4 serology among Malaysians. Mult Sclerosis Relat Disord. 2017;12:34–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28283103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cao G, Duan Y, Zhang N, Sun J, Li H, Li Y, et al. Brain MRI characteristics in neuromyelitis optica spectrum disorders: a large multi‐center retrospective study in China. Mult Sclerosis Relat Disord. 2020;46:102475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32898832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Long Y, Chen M, Zhang B, Gao C, Zheng Y, Xie L, et al. Brain gadolinium enhancement along the ventricular and leptomeningeal regions in patients with aquaporin‐4 antibodies in cerebral spinal fluid. J Neuroimmunol. 2014;269:62–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24582827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim W, Lee JE, Kim SH, Huh SY, Hyun JW, Jeong IH, et al. Cerebral cortex involvement in neuromyelitis optica spectrum disorder. J Clin Neurol. 2016;12:188–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4828565</ArticleId>
            <ArticleId IdType="pubmed">26833983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wengert O, Rothenfusser‐Korber E, Vollrath B, Bohner G, Scheibe F, Otto C, et al. Neurosarcoidosis: correlation of cerebrospinal fluid findings with diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity. J Neurol Sci. 2013;335:124–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24071064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nakamura M, Misu T, Fujihara K, Miyazawa I, Nakashima I, Takahashi T, et al. Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Sclerosis. 2009;15:695–700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19435750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim SH, Hyun JW, Joung A, Lee SH, Kim HJ. Occurrence of asymptomatic acute neuromyelitis optica spectrum disorder‐typical brain lesions during an attack of optic neuritis or myelitis. PLOS ONE. 2016;11:e0167783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5147946</ArticleId>
            <ArticleId IdType="pubmed">27936193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wilson CA, Mullen MT, Jackson BP, Ishida K, Messe SR. Etiology of corpus callosum lesions with restricted diffusion. Clin Neuroradiol. 2017;27:31–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26031431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Oliveira P, Mayeux J. Teaching neuroimages: snowball‐like lesions with sudden hearing loss. Neurology
2014;82:e100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24663235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Renard D, Castelnovo G, Bousquet PJ, de Champfleur
N
, de Seze
J
, Vermersch P, et al. Brain MRI findings in long‐standing and disabling multiple sclerosis in 84 patients. Clin Neurol Neurosurg. 2010;112:286–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20061078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang F, Liu Y, Duan Y, Li K. Brain MRI abnormalities in neuromyelitis optica. Eur J Radiol. 2011;80:445–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20884147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang L, Wu A, Zhang B, Chen S, Men X, Lin Y, et al. Comparison of deep gray matter lesions on magnetic resonance imaging among adults with acute disseminated encephalomyelitis, multiple sclerosis, and neuromyelitis optica. Mult Sclerosis. 2014;20:418–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23886831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ito S, Mori M, Makino T, Hayakawa S, Kuwabara S. ‘Cloud‐like enhancement’ is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol. 2009;66:425–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19798642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim SH, Huh SY, Hyun JW, Jeong IH, Lee SH, Joung A, et al. A longitudinal brain magnetic resonance imaging study of neuromyelitis optica spectrum disorder. PLOS ONE. 2014;9:e108320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4178152</ArticleId>
            <ArticleId IdType="pubmed">25259647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cabrera‐Gomez JA, Quevedo‐Sotolongo L, Gonzalez‐Quevedo A, Lima S, Real‐Gonzalez Y, Cristofol‐Corominas M, et al. Brain magnetic resonance imaging findings in relapsing neuromyelitis optica. Mult Sclerosis. 2007;13:186–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17439883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pires CE, Silva CM, Lopes FC, Malfetano FR, Pereira VC, Kubo T, et al. Brain MRI abnormalities in Brazilian patients with neuromyelitis optica. J Clin Neurosci. 2012;19:969–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22613491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liao MF, Chang KH, Lyu RK, Huang CC, Chang HS, Wu YR, et al. Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients. BMC Neurol. 2014;14:218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4264553</ArticleId>
            <ArticleId IdType="pubmed">25433369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Banker P, Sonni S, Kister I, Loh JP, Lui YW. Pencil‐thin ependymal enhancement in neuromyelitis optica spectrum disorders. Mult Sclerosis. 2012;18:1050–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22183933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cabrera‐Gomez J, Saiz‐Hinarejos A, Graus F, Gonzalez‐Quevedo A, Rodriguez‐Rojas R, Quevedo‐Sotolongo L, et al. Brain magnetic resonance imaging findings in acute relapses of neuromyelitis optica spectrum disorders. Mult Sclerosis. 2008;14:248–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18208893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Makino T, Ito S, Mori M, Yonezu T, Ogawa Y, Kuwabara S. Diffuse and heterogeneous T2‐hyperintense lesions in the splenium are characteristic of neuromyelitis optica. Mult Sclerosis. 2013;19:308–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22809881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kruit MC, van Buchem
MA
, Launer LJ, Terwindt GM, Ferrari MD. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population‐based MRI CAMERA study. Cephalalgia
2010;30:129–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3241741</ArticleId>
            <ArticleId IdType="pubmed">19515125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Matsushita T, Isobe N, Piao H, Matsuoka T, Ishizu T, Doi H, et al. Reappraisal of brain MRI features in patients with multiple sclerosis and neuromyelitis optica according to anti‐aquaporin‐4 antibody status. J Neurol Sci. 2010;291:37‐43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20122699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Absoud M, Lim MJ, Appleton R, Jacob A, Kitley J, Leite MI, et al. Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features. J Neurol Neurosurg Psychiatry. 2015;86:470–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25091363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ikeda K, Ito H, Hidaka T, Takazawa T, Sekine T, Yoshii Y, et al. Repeated non‐enhancing tumefactive lesions in a patient with a neuromyelitis optica spectrum disorder. Intern Med. 2011;50:1061–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21532234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Matthews L, Marasco R, Jenkinson M, Kuker W, Luppe S, Leite MI, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology
2013;80:1330–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3656462</ArticleId>
            <ArticleId IdType="pubmed">23486868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Magana SM, Matiello M, Pittock SJ, McKeon A, Lennon VA, Rabinstein AA, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology
2009;72:712–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19237699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Berger JR, Neltner J, Smith C, Cambi F. Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica. Mult Sclerosis Relat Disord. 2014;3:728–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25891552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Igel C, Garretto D, Robbins MS, Swerdlow M, Judge N, Dayal A. Neuromyelitis optica in pregnancy complicated by posterior reversible encephalopathy syndrome, eclampsia and fetal death. J Clin Med Res. 2015;7:193–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4285068</ArticleId>
            <ArticleId IdType="pubmed">25584107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corbett J, Bhuta S, Prain K, Brilot F, Sabet A, Broadley SA. PRES‐like presentation in MOG antibody‐related demyelination (MARD). J Clin Neurosci. 2020;72:453–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31982280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kulkarni GB, Kallollimath P, Subasree R, Veerendrakumar M. Intractable vomiting and hiccups as the presenting symptom of neuromyelitis optica. Ann Ind Acad Neurol. 2014;17:117–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3992749</ArticleId>
            <ArticleId IdType="pubmed">24753677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Popescu BF, Lennon VA, Parisi JE, Howe CL, Weigand SD, Cabrera‐Gomez JA, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology
2011;76:1229–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3068006</ArticleId>
            <ArticleId IdType="pubmed">21368286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pedigo NW Jr, Brizzee KR. Muscarinic cholinergic receptors in area postrema and brainstem areas regulating emesis. Brain Res Bull. 1985;14:169–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3995361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology
2005;65:1479–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16275842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Etemadifar M, Sabeti F, Ebrahimian S, Momeni F. Dorsal midbrain involvement in MRI as a core clinical manifestation for NMOSD diagnosis. Mult Sclerosis Relat Disord. 2020;43:102150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32416559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lemos MD, Carvalho GB, Carvalho RS, Bichuetti DB, de Oliveira
EM
, Abdala N. Neuromyelitis optica spectrum disorders: beyond longitudinally extensive transverse myelitis. Clin Radiol. 2015;70:630–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25861875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim JE, Kim SM, Ahn SW, Lim BC, Chae JH, Hong YH, et al. Brain abnormalities in neuromyelitis optica. J Neurol Sci. 2011;302:43–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21236446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Toru S, Soejima I, Katayama Y, Saito K, Yokote H. A case of anti‐AQP4 antibody‐positive neuromyelitis optica spectrum disorder with MRI‐proven lesions in lumbar nerve roots. Mult Sclerosis Relat Disord. 2020;46:102557.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33296967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sinnecker T, Schumacher S, Mueller K, Pache F, Dusek P, Harms L, et al. MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7T. Neurol Neuroimmunol Neuroinflamm. 2016;3:e259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4959510</ArticleId>
            <ArticleId IdType="pubmed">27489865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chawla S, Ge Y, Wuerfel J, Asadollahi S, Mohan S, Paul F, et al. Longitudinal ultra‐high field MRI of brain lesions in neuromyelitis optica spectrum disorders. Mult Sclerosis Relat Disord. 2020;42:102066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7410392</ArticleId>
            <ArticleId IdType="pubmed">32272444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jang J, Nam Y, Choi Y, Shin NY, An JY, Ahn KJ, et al. Paramagnetic rims in multiple sclerosis and neuromyelitis optica spectrum disorder: a quantitative susceptibility mapping study with 3‐T MRI. J Clin Neurol. 2020;16:562–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7542003</ArticleId>
            <ArticleId IdType="pubmed">33029961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pasquier B, Borisow N, Rasche L, Bellmann‐Strobl J, Ruprecht K, Niendorf T, et al. Quantitative 7T MRI does not detect occult brain damage in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2019;6:e541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6410932</ArticleId>
            <ArticleId IdType="pubmed">30882018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pache F, Zimmermann H, Finke C, Lacheta A, Papazoglou S, Kuchling J, et al. Brain parenchymal damage in neuromyelitis optica spectrum disorder – a multimodal MRI study. Eur Radiol. 2016;26:4413–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27012555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang N, Sun J, Wang Q, Qin W, Zhang X, Qi Y, et al. Differentiate aquaporin‐4 antibody negative neuromyelitis optica spectrum disorders from multiple sclerosis by multimodal advanced MRI techniques. Mult Sclerosis Relat Disord. 2020;41:102035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32200338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Aboul‐Enein F, Krssak M, Hoftberger R, Prayer D, Kristoferitsch W. Diffuse white matter damage is absent in neuromyelitis optica. Am J Neuroradiol. 2010;31:76–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7964054</ArticleId>
            <ArticleId IdType="pubmed">19749224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pichiecchio A, Tavazzi E, Poloni G, Ponzio M, Palesi F, Pasin M, et al. Advanced magnetic resonance imaging of neuromyelitis optica: a multiparametric approach. Mult Sclerosis. 2012;18:817–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22183930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schmidt FA, Chien C, Kuchling J, Bellmann‐Strobl J, Ruprecht K, Siebert N, et al. Differences in advanced magnetic resonance imaging in MOG‐IgG and AQP4‐IgG seropositive neuromyelitis optica spectrum disorders: a comparative study. Front Neurol. 2020;11. doi:10.3389/fneur.2020.499910499910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2020.499910499910</ArticleId>
            <ArticleId IdType="pmc">PMC7554609</ArticleId>
            <ArticleId IdType="pubmed">33101166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chanson JB, Lamy J, Rousseau F, Blanc F, Collongues N, Fleury M, et al. White matter volume is decreased in the brain of patients with neuromyelitis optica. Eur J Neurol. 2013;20:361–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22978568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Calabrese M, Oh MS, Favaretto A, Rinaldi F, Poretto V, Alessio S, et al. No MRI evidence of cortical lesions in neuromyelitis optica. Neurology
2012;79:1671–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22993282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asseyer S, Kuchling J, Gaetano L, Komnenic D, Siebert N, Chien C, et al. Ventral posterior nucleus volume is associated with neuropathic pain intensity in neuromyelitis optica spectrum disorders. Mult Sclerosis Relat Disord. 2020;46. doi:10.1016/j.msard.2020.102579102579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2020.102579102579</ArticleId>
            <ArticleId IdType="pubmed">33296976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Papadopoulou A, Oertel FC, Gaetano L, Kuchling J, Zimmermann H, Chien C, et al. Attack‐related damage of thalamic nuclei in neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2019;90:1156–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31127016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chien C, Oertel FC, Siebert N, Zimmermann H, Asseyer S, Kuchling J, et al. Imaging markers of disability in aquaporin‐4 immunoglobulin G seropositive neuromyelitis optica: a graph theory study. Brain Commun. 2019;1. doi:10.1093/braincomms/fcz026fcz026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/braincomms/fcz026fcz026</ArticleId>
            <ArticleId IdType="pmc">PMC7425339</ArticleId>
            <ArticleId IdType="pubmed">32954267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Juenger V, Cooper G, Chien C, Chikermane M, Oertel FC, Zimmermann H, et al. Optic chiasm measurements may be useful markers of anterior optic pathway degeneration in neuromyelitis optica spectrum disorders. Eur Radiol. 2020;30:5048–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7431438</ArticleId>
            <ArticleId IdType="pubmed">32335748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rocca MA, Agosta F, Mezzapesa DM, Falini A, Martinelli V, Salvi F, et al. A functional MRI study of movement‐associated cortical changes in patients with Devic’s neuromyelitis optica. NeuroImage
2004;21:1061–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15006674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu Y, Liang P, Duan Y, Jia X, Wang F, Yu C, et al. Abnormal baseline brain activity in patients with neuromyelitis optica: a resting‐state fMRI study. Eur J Radiol. 2011;80:407–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20605694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu Y, Xiong H, Li X, Zhang D, Yang C, Yu J, et al. Abnormal baseline brain activity in neuromyelitis optica patients without brain lesion detected by resting‐state functional magnetic resonance imaging. Neuropsychiatr Dis Treat. 2020;16:71–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6955618</ArticleId>
            <ArticleId IdType="pubmed">32021200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim H, Lee Y, Kim YH, Lim YM, Lee JS, Woo J, et al. Deep Learning‐based method to differentiate neuromyelitis optica spectrum disorder from multiple sclerosis. Front Neurol. 2020;11:599042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7734316</ArticleId>
            <ArticleId IdType="pubmed">33329357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maillart E, Lippi A, Lubetzki C, Louapre C, Papeix C. Early relapse after RTX initiation in a patient with NMO/MS overlap syndrome: How long to conclude to a failure treatment?
Mult Sclerosis Relat Disord. 2018;20:220–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29433095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Murchison A, Kitley J, Leite MI, Kuker W, Palace J. Predictive value of MRI parameters in severity and recovery of first‐episode myelitis in aquaporin‐4 antibody disease. J Neurol Sci. 2015;355:49–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26026944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bonnan M, Debeugny S, Mejdoubi M, Cabre P. Predictive value of conventional MRI parameters in first spinal attacks of neuromyelitis optica spectrum disorder. Mult Sclerosis. 2020;26:468–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30843448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xu Y, Ren Y, Li X, Xu W, Wang X, Duan Y, et al. Persistently gadolinium‐enhancing lesion is a predictor of poor prognosis in NMOSD attack: a clinical trial. Neurotherapeutics
2021. doi:10.1007/s13311-020-00973-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-020-00973-9</ArticleId>
            <ArticleId IdType="pmc">PMC8423888</ArticleId>
            <ArticleId IdType="pubmed">33469828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jurynczyk M, Messina S, Palace J. Spinal cord and brain MRI should be routinely performed during follow‐up in patients with NMOSD – no. Mult Sclerosis. 2021;27:15–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33141633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee MY, Yong KP, Hyun JW, Kim SH, Lee SH, Kim HJ. Incidence of interattack asymptomatic brain lesions in NMO spectrum disorder. Neurology
2020;95:e3124–e8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32928976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cai MT, Zheng Y, Shen CH, Yang F, Fang W, Zhang YX, et al. Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody‐associated disorder. Mult Sclerosis. 2020;1352458520939008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32672091</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
